Posted On: 01/10/2016 4:06:33 PM
Post# of 72443
This has me wondering if at some point the software used to develop Brilacidin could be used to develop a compound that would work on cancer cells like Brilacidin works on bacteria.
""Cancer therapies that attack the lipid composition of the cell membrane would be an entirely new class of anticancer drugs," says co-senior study author Paul Beales, of the University of Leeds in the UK. "This could be useful in developing new combination therapies, where multiple drugs are used simultaneously to treat a cancer by attacking different parts of the cancer cells at the same time."
MP1 acts against microbial pathogens by disrupting the bacterial cell membrane. Serendipitously, the antimicrobial peptide shows promise for protecting humans from cancer; it can inhibit the growth of prostate and bladder cancer cells, as well as multi-drug resistant leukemic cells. However, until now, it was not clear how MP1 selectively destroys cancer cells without harming normal cells."
http://m.phys.org/news/2015-09-brazilian-wasp...cells.html
"... testing new defensin imitators, known as defensin mimetics, they turned to computer-simulation technology.
A company was formed in 2002 to further develop the three-dimensional molecular modeling programs created at the University of Pennsylvania. With increasingly sophisticated computers and software at their service, Polymedix performed in silico experiments on a vast number of possible defensin-based molecules.
Many promising molecules were found, and the lead compound got all the way to a Phase 2a study. Perhaps the most meaningful sign of the designers’ success is that these simplified defensin molecules do not only kill bacteria on contact, they exhibit other beneficial immune-system characteristics typical of natural defensins. Moreover, these synthetic defensins, like natural defensins, interact only with the outer membrane of bacteria. Consequently, the chances that resistance can develop are radically if not completely reduced.
""Cancer therapies that attack the lipid composition of the cell membrane would be an entirely new class of anticancer drugs," says co-senior study author Paul Beales, of the University of Leeds in the UK. "This could be useful in developing new combination therapies, where multiple drugs are used simultaneously to treat a cancer by attacking different parts of the cancer cells at the same time."
MP1 acts against microbial pathogens by disrupting the bacterial cell membrane. Serendipitously, the antimicrobial peptide shows promise for protecting humans from cancer; it can inhibit the growth of prostate and bladder cancer cells, as well as multi-drug resistant leukemic cells. However, until now, it was not clear how MP1 selectively destroys cancer cells without harming normal cells."
http://m.phys.org/news/2015-09-brazilian-wasp...cells.html
"... testing new defensin imitators, known as defensin mimetics, they turned to computer-simulation technology.
A company was formed in 2002 to further develop the three-dimensional molecular modeling programs created at the University of Pennsylvania. With increasingly sophisticated computers and software at their service, Polymedix performed in silico experiments on a vast number of possible defensin-based molecules.
Many promising molecules were found, and the lead compound got all the way to a Phase 2a study. Perhaps the most meaningful sign of the designers’ success is that these simplified defensin molecules do not only kill bacteria on contact, they exhibit other beneficial immune-system characteristics typical of natural defensins. Moreover, these synthetic defensins, like natural defensins, interact only with the outer membrane of bacteria. Consequently, the chances that resistance can develop are radically if not completely reduced.
(0)
(0)Scroll down for more posts ▼
